secwatch / observer
8-K filed June 23, 2025, 7:59 PM ET ticker HBIO CIK 0001123494
regulatory confidence high sentiment negative materiality 0.55

HARVARD BIOSCIENCE INC (HBIO): Nasdaq/NYSE listing notice — Harvard Bioscience out of compliance with Nasdaq audit committee rule after board resignation

HARVARD BIOSCIENCE INC

item 3.01item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

HARVARD BIOSCIENCE INC received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2)(A), 5605(c)(4)).

Exchange
nasdaq
Notice
deficiency notice
Deficiency
audit committee
Rules
5605(c)(2)(A), 5605(c)(4)
Exact text from the filing
June 18, 2025, Harvard Biosci e nce, Inc. (the “Company”) notified the Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with the audit committee requirement set forth in Nasdaq Listing Rule 5605(c)(2)(A) (the “Audit Committee Composition Requirement”) due to the Company having only two members on the audit committee (the “Audit Committee”) of its Board of Directors (the “Board”). The Company’s current failure to comply with the Audit Committee Composition Requirement is due to a vacancy resulting from Alan Edrick’s resignation from the Board and the Audit Committee effe
View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

HARVARD BIOSCIENCE INC filing history →

Source: SEC EDGAR
accession 0001171843-25-004036
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.